Yazılar

Ubisoft Delays ‘Assassin’s Creed Shadows’ Release Again

/in /tarafından

Ubisoft has announced a further delay in the release of Assassin’s Creed Shadows, pushing the launch from February 14 to March 20. This marks the second delay for the highly anticipated game in the Assassin’s Creed series, with the original release date being set for November before being postponed in September.

The additional month will allow the development team more time to incorporate player feedback from the previous months, aiming to refine the game further before its official release. Ubisoft has highlighted that the feedback from the Assassin’s Creed community has been increasingly positive, and the extended time will help to ensure the best possible launch conditions.

This delay adds to Ubisoft’s recent struggles, which include a disappointing reception for Star Wars Outlaws, released in August 2024, that did not meet sales expectations. As a result, Ubisoft’s shares have halved in value over the past year.

Additionally, Ubisoft revealed plans for significant restructuring after a strategic review, including appointing advisers to explore options for improving stakeholder value. The company aims to reduce its fixed cost base by more than €200 million by FY2025-26 and take a more selective approach to investments.

For the third quarter, Ubisoft forecasts net bookings around €300 million, a significant drop from earlier projections due to weak holiday sales and the discontinuation of XDefiant.

 

Can New CVS CEO David Joyner Overcome the Aetna Challenge?

/in /tarafından

With CVS Health’s recent leadership transition, David Joyner faces a tough road ahead as the new CEO, following the sudden departure of Karen Lynch. While Joyner’s previous role involved overseeing Caremark, CVS’s pharmacy benefit management (PBM) business, questions arise about whether his experience equips him to tackle the significant challenges facing Aetna, the health insurance division.

Aetna has been struggling with rising medical costs, particularly in its Medicare Advantage plans for seniors, reflecting broader industry issues but more acutely affecting CVS. Joyner’s appointment coincided with the company’s decision to withdraw its 2024 earnings forecast and warn of disappointing third-quarter profits, sending CVS shares down 5%. Over the past year, CVS stock has dropped 24%, lagging far behind the broader market’s gains.

Wall Street analysts and investors have expressed concern over Joyner’s lack of direct experience in health insurance and public company leadership. Andrew Mok, a Barclays analyst, pointed to a “leadership gap at Aetna” that needs urgent attention, echoing the doubts of several others. Aetna’s struggles, including its rising medical services costs, have exacerbated investor worries, with the company paying out 95% of premiums for medical services—well above the target ratio of 80%.

Joyner, however, insists he’s ready for the challenge. In a joint interview with Executive Chairman Roger Farah, who described the board’s selection process as “very thorough,” Joyner defended his qualifications and stressed his commitment to addressing Aetna’s issues. He plans to form a new management team, including leadership for Aetna, which has been without a permanent head since the departure of Brian Kane two months ago. Lynch had been overseeing Aetna during this interim period.

Some analysts remain optimistic about Joyner’s appointment. Lisa Gill from J.P. Morgan recalled his past success in revitalizing Caremark in the early 2000s and praised his direct, candid management style, believing it could prove valuable as CVS navigates through these turbulent times.

CVS’s strategic review also revealed plans to sell off non-core assets and close 271 retail pharmacies as the company seeks to improve efficiency. However, speculation around a potential breakup of CVS’s pharmacy and insurance businesses persists. Farah acknowledged these discussions but affirmed that the company’s leadership believes in the value of keeping the divisions together, focusing instead on executing better.

With his experience and an ambitious agenda, Joyner must now work to stabilize Aetna, rebuild investor confidence, and chart a path forward for CVS in an increasingly competitive healthcare market.